Nuvation Bio Inc. (NYSE:NUVB) Short Interest Update

Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 20,940,000 shares, an increase of 35.9% from the December 15th total of 15,410,000 shares. Currently, 9.1% of the company's stock are short sold. Based on an average daily volume of 2,320,000 shares, the days-to-cover ratio is presently 9.0 days.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NUVB. B. Riley Wealth Advisors Inc. purchased a new position in Nuvation Bio in the 2nd quarter valued at $29,000. EverSource Wealth Advisors LLC raised its position in Nuvation Bio by 913.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 11,095 shares of the company's stock worth $32,000 after buying an additional 10,000 shares during the last quarter. Xponance Inc. acquired a new stake in shares of Nuvation Bio in the 2nd quarter worth $33,000. Caxton Associates LP acquired a new position in shares of Nuvation Bio during the second quarter worth about $43,000. Finally, Choreo LLC acquired a new position in shares of Nuvation Bio during the second quarter worth about $47,000. Institutional investors and hedge funds own 61.67% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on NUVB shares. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Nuvation Bio in a report on Monday, January 6th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Finally, Wedbush restated an "outperform" rating and issued a $5.00 price objective on shares of Nuvation Bio in a research note on Monday, January 6th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Nuvation Bio presently has an average rating of "Buy" and a consensus target price of $7.40.

Nuvation Bio Trading Down 2.5 %

NUVB stock traded down $0.07 on Thursday, hitting $2.54. The company's stock had a trading volume of 2,815,798 shares, compared to its average volume of 3,305,980. The stock has a market cap of $853.20 million, a price-to-earnings ratio of -1.17 and a beta of 1.47. The firm has a 50 day moving average of $2.78 and a two-hundred day moving average of $2.82. Nuvation Bio has a 1 year low of $1.43 and a 1 year high of $4.16.

Nuvation Bio (NYSE:NUVB - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The firm had revenue of $0.73 million for the quarter. As a group, equities analysts forecast that Nuvation Bio will post -0.36 EPS for the current fiscal year.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.